ALISA SELIMOVIC

Board Observer

Alisa is Investment Manager Life Sciences at IP Group Australia, where she is responsible for evaluating and progressing toward investment new life science technologies from our university partners in Australia and NZ.

Prior to her return to Australia in 2017, Alisa spent eight years in Oxford, UK, where she worked in life sciences strategy and M&A consulting at PharmaVentures, and in the Corporate Development team at Circassia, where she worked on the company’s £275M acquisition of Prosonix and Aerocrine.

Alisa holds a PhD in Biomedical Engineering from Oxford, and a Bachelor of Engineering / Bachelor of Life Sciences from Flinders University.